MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Levodopa(L-dopa)"

  • 2019 International Congress

    Estimating the long-term effect of early levodopa treatment initiation in Parkinson’s disease

    L. Vd Heuvel, J. Krijthe, L. Evers, M. Meinders, B. Post, T. Heskes, B. Bloem (Nijmegen, Netherlands)

    Objective: Using observational longitudinal data to estimate the long-term effect of the duration of levodopa treatment in the first two years after diagnosis. Background: Levodopa…
  • 2019 International Congress

    Deep Brain Stimulation as a Rescue When Duodenal Levodopa Infusion Fails: Report of 2 Cases

    N. Nathoo, T. Sankar, O. Suchowersky, F. Ba (Edmonton, AB, Canada)

    Objective: To describe two cases of patients with Parkinson’s disease (PD) where deep brain stimulation (DBS) was used a rescue therapy when duodenal levodopa infusion…
  • 2019 International Congress

    Design, characterization and In vivo evaluation of intranasal delivery of levodopa loaded microspere for Parkinsonism

    S. Jain, A. Jain, SB. Bhargav (Sagar, India)

    Objective: Levodopa is the drug of choice in the treatment of Parkinson's disease but it exhibits low oral bioavailability and very low brain uptake. The…
  • 2019 International Congress

    Sudden alopecia secondary to levodopa treatment

    N. Garcia Alvarado, N. López Ariztegui, MI. Morales Casado, JC. Segundo Rodríguez, C. Schoendorff Ortega, R. Almansa Castillo, JA. Perez Matos, A. ávila Fernández, C. Marsal Alonso (Toledo, Spain)

    Objective: Report a rarely documented side effect of dopaminergic therapy and review the literature on this aspect, highlighting the underlying mechanisms hypothetically involved. Background: Levodopa…
  • 2019 International Congress

    Levodopa response in later stages of Parkinson’s disease: a case-control study

    M. Fabbri, M. Coelho, D. Abreu, L. Guedes, M. Rosa, A. Antonini, J. Ferreira (Lisbon, Portugal)

    Objective: To compare the response of motor and non-motor symptoms (NMS) to a L-dopa challenge test  between late stage (LS) PD patients and advanced stage…
  • 2019 International Congress

    Factors associated with dyskinesia in Parkinson’s disease in Mainland China

    X. Zhou, LF. Fang, XT. Zhou, XX. Zhou, YW. Zhao, LX. Qin, Y. Tian, ZQ. Wang, QY. Sun, Q. Xu, JC. Li, JF. Guo, XX. Yan, BS. Tang (Changsha, China)

    Objective: To identify the association between dyskinesia and related risk factors, the medication dosage range considered safe and treatment-related variables.To identify the association between dyskinesia…
  • 2019 International Congress

    Levodopa-responsive tremor in a young child as a delayed complication of osmotic demyelination from severe hypernatremia

    L. Tochen, M. Cameron, C. Brady, M. Fleming (Washington, DC, USA)

    Objective: To describe a case of levodopa responsive tremor due to osmotic demyelination as a result of severe hypernatremia Background: Osmotic demyelination is a known…
  • 2019 International Congress

    Opicapone and levodopa-carbidopa intestinal gel infusion: a cost saving analysis in the United Kingdom

    V. Leta, D. van Wamelen, A. Sauerbier, S. Jones, A. Podlewska, D. Trivedi, M. Parry, P. Odin, A. Storch, Z. Pirtošek, A. Antonini, K. Ray Chaudhuri (London, United Kingdom)

    Objective: To investigate whether the use of Opicapone as an add-on therapy to levodopa-carbidopa intestinal gel (LCIG) infusion in advanced Parkinson’s disease (PD) reduces the…
  • 2019 International Congress

    Effect of gastrointestinal surgery on the pharmacokinetics of levodopa in Parkinson’s disease

    N. Miyaue, M. Nomoto, H. Yabe, Y. Yamanishi, S. Tada, R. Ando, M. Kubo, M. Nagai (Ehime, Japan)

    Objective: The aim of this study is to evaluate the pharmacokinetics of levodopa in patients with Parkinson’s disease (PD) who underwent gastrointestinal surgery. Background: Levodopa…
  • 2019 International Congress

    Long-term effect of levodopa-carbidopa intestinal gel on axial signs in Parkinson’s disease

    M. Fabbri, P. Chatkaew, C. Artusi, A. Romagnolo, M. Rizzone, M. Zibetti, L. Lopiano (Turin, Italy)

    Objective: To investigate the long-term effect of levodopa-carbidopa intestinal gel (LCIG) on axial signs in Parkinson's disease (PD) patients and the related prognostic factors. Background:…
  • « Previous Page
  • 1
  • …
  • 36
  • 37
  • 38
  • 39
  • 40
  • …
  • 62
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley